Blueprint Medicines Q4 2022 Earnings Report $90.14 +1.21 (+1.36%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Blueprint Medicines EPS ResultsActual EPS-$2.65Consensus EPS -$2.73Beat/MissBeat by +$0.08One Year Ago EPS-$0.99Blueprint Medicines Revenue ResultsActual Revenue$38.78 millionExpected Revenue$33.52 millionBeat/MissBeat by +$5.26 millionYoY Revenue Growth-63.80%Blueprint Medicines Announcement DetailsQuarterQ4 2022Date2/16/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseBPMC Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Blueprint Medicines Earnings HeadlinesInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells 15,000 Shares of StockDecember 23 at 4:15 AM | americanbankingnews.comBlueprint Medicines' SWOT analysis: stock's potential in precision oncologyDecember 20 at 10:53 PM | uk.investing.comThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…December 23, 2024 | Crypto 101 Media (Ad)J.P. Morgan’s top Healthcare stocks for 2025December 20 at 12:52 PM | msn.comBlueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2024 | prnewswire.comAnalysts Set Blueprint Medicines Co. (NASDAQ:BPMC) Price Target at $122.11December 14, 2024 | americanbankingnews.comSee More Blueprint Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Blueprint Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Blueprint Medicines and other key companies, straight to your email. Email Address About Blueprint MedicinesBlueprint Medicines (NASDAQ:BPMC), a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.View Blueprint Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
